Finasteride in hair loss is one of the most evidence-based treatments available for male pattern baldness in the UK. Licensed at 1 mg daily, finasteride works by reducing dihydrotestosterone (DHT), the hormone responsible for shrinking hair follicles in androgenetic alopecia. Used consistently, it can slow hair loss and, in many cases, stimulate partial regrowth. This article explains how finasteride works, who it is suitable for, what to expect from treatment, its recognised side effects including updated MHRA safety guidance, and how to access it through private or NHS routes in the UK.
Summary: Finasteride treats male pattern hair loss by inhibiting 5-alpha reductase to reduce DHT levels, slowing follicle miniaturisation and, in many cases, stimulating partial regrowth with daily 1 mg use.
- Finasteride 1 mg is licensed in the UK for androgenetic alopecia in adult men aged 18 and over; it is not licensed for women with hair loss.
- It works by blocking the type II 5-alpha reductase enzyme, reducing circulating DHT by approximately 60–70%.
- Visible results typically take 3–6 months; maximum benefit is usually achieved after around 2 years of continuous daily use.
- The MHRA (2024) strengthened warnings on psychiatric side effects, including depression and suicidal thoughts; a patient alert card is now issued with finasteride 1 mg.
- Finasteride reduces PSA levels by approximately 50%, which must be accounted for when interpreting prostate cancer screening results.
- Finasteride for hair loss is not routinely available on the NHS and is usually accessed via private prescription from a CQC-registered provider.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
How Finasteride Works to Treat Hair Loss
Finasteride inhibits the type II 5-alpha reductase enzyme, reducing DHT levels by 60–70% and slowing the follicle miniaturisation that drives androgenetic alopecia. Benefits depend on continued use, as DHT returns to baseline within weeks of stopping.
Finasteride is an oral medication that works by inhibiting the enzyme 5-alpha reductase, specifically the type II isoform. This enzyme is responsible for converting testosterone into dihydrotestosterone (DHT), a potent androgen that plays a central role in androgenetic alopecia — the most common form of hair loss in men. By reducing circulating DHT levels by approximately 60–70% (as reported in the UK Summary of Product Characteristics for finasteride 1 mg), finasteride helps to slow the miniaturisation of hair follicles that characterises this condition.
Not sure if this is normal? Chat with one of our pharmacists →
In androgenetic alopecia, genetically susceptible hair follicles are particularly sensitive to DHT. Over time, repeated exposure causes follicles to shrink progressively, producing finer, shorter hairs until they eventually cease production altogether. Finasteride interrupts this process by reducing the hormonal signal that drives follicle miniaturisation, thereby helping to preserve existing hair and, in many cases, stimulating partial regrowth in areas where follicles remain viable.
It is important to understand that finasteride does not permanently alter hair follicle genetics. Its benefits are dependent on continued use — if treatment is stopped, DHT levels return to baseline within weeks, and hair loss typically resumes within 6 to 12 months, as noted in the product SmPC. This makes finasteride a long-term management strategy rather than a cure. The medication is licensed in the UK at a 1 mg daily dose specifically for the treatment of androgenetic alopecia in adult men (aged 18 years and over), and at 5 mg for benign prostatic hyperplasia, reflecting its broader pharmacological utility.
| Side Effect | Frequency | Severity | Management |
|---|---|---|---|
| Decreased libido, erectile dysfunction, ejaculatory disorder | ~1–4% in clinical trials | Mild to moderate; generally reversible on stopping | Discuss with prescriber before altering treatment; report via MHRA Yellow Card |
| Depression, anxiety, thoughts of self-harm or suicide | Uncommon; MHRA 2024 strengthened warning | Potentially severe | Stop finasteride immediately; contact GP or attend nearest emergency department |
| Persistent sexual and psychiatric symptoms post-discontinuation | Reported; exact frequency uncertain | Potentially severe; causality under regulatory review | Counsel patients before starting; report to MHRA Yellow Card scheme |
| Reduced PSA levels (~50% after ≥6 months) | Expected pharmacological effect | Clinically significant for prostate cancer screening | Double PSA result to obtain corrected estimate; investigate any rise from nadir |
| Gynaecomastia (breast tenderness or enlargement) | Uncommon | Mild to moderate | Assess any persistent breast changes to exclude other pathology |
| Male breast cancer | Rare; cases reported post-marketing | Serious | Seek prompt medical review for any breast lump, pain, or nipple discharge |
| Hypersensitivity reactions (rash, urticaria, angioedema) | Rare | Potentially serious | Stop medication immediately; seek urgent medical advice |
Who Is Finasteride Suitable For in the UK?
Finasteride 1 mg is licensed only for adult men aged 18 and over with androgenetic alopecia; it must not be used by women who are pregnant or may become pregnant. Other causes of hair loss, such as alopecia areata or thyroid dysfunction, will not respond to finasteride.
In the UK, finasteride 1 mg (marketed as Propecia and available as generics) is licensed for use in adult men only (aged 18 years and over) for the treatment of androgenetic alopecia, commonly known as male pattern baldness. It is most effective in men experiencing hair thinning at the crown or mid-scalp, and clinical evidence suggests it is less effective for a receding frontal hairline, though some benefit may still be observed.
Finasteride is not licensed for use in women in the UK for hair loss. The Medicines and Healthcare products Regulatory Agency (MHRA) advises that finasteride must not be used by women who are pregnant or may become pregnant, as it can cause abnormalities of the external genitalia in a male foetus. Intact film-coated tablets may be handled safely; however, women who are or may become pregnant must not handle crushed or broken tablets, as absorption through the skin is possible. Some specialist dermatologists may consider off-label use in post-menopausal women with androgenetic alopecia, but this falls outside standard licensed indications and requires careful clinical judgement.
Candidates for finasteride should be assessed to confirm the diagnosis of androgenetic alopecia, as other causes of hair loss will not respond to this treatment. Clinicians should be alert to red flags that suggest an alternative diagnosis and warrant further evaluation or referral, including: sudden or patchy hair loss, signs of scarring alopecia, scalp inflammation or scaling, associated systemic symptoms (such as fatigue, weight change, or skin changes), or diagnostic uncertainty. Conditions such as alopecia areata, telogen effluvium, and thyroid dysfunction require different management.
A baseline medical history should be taken, including any history of liver disease, prostate conditions, or mood disorders, as these may influence prescribing decisions. Finasteride should be used with caution in men with hepatic impairment, as per the SmPC. Men with a family history of prostate cancer should discuss this with their prescriber, since finasteride lowers PSA (prostate-specific antigen) levels, which can affect prostate cancer screening interpretation (see the side effects section for further detail).
Experiencing these side effects? Our pharmacists can help you navigate them →
Dosage, Administration, and What to Expect
The licensed dose is 1 mg orally once daily; visible slowing of hair loss may occur within 3–6 months, with measurable regrowth typically apparent after 6–12 months. Discontinuation reverses any gains within approximately 9–12 months.
The standard licensed dose of finasteride for male pattern hair loss in the UK is 1 mg taken orally once daily. The tablet should be swallowed whole and can be taken with or without food. Consistency is key — taking finasteride at the same time each day helps maintain stable DHT suppression and supports treatment adherence.
Patients should be counselled that finasteride does not produce immediate results. Based on pivotal clinical trial data and the UK SmPC:
-
Visible slowing of hair loss may be noticed within 3 to 6 months of consistent use.
-
Measurable hair regrowth typically becomes apparent after 6 to 12 months.
-
Maximum benefit is generally achieved after approximately 2 years of continuous treatment.
In pivotal randomised controlled trials, the majority of men taking finasteride 1 mg maintained or increased their hair count over two years, compared with significant continued loss in the placebo group. However, individual responses vary, and a minority of men may not respond meaningfully to treatment. Patients should be advised that if no meaningful benefit is apparent after 12 months of consistent use, discontinuation may be appropriate following discussion with their prescriber.
An early follow-up appointment at 3 to 6 months is advisable to review adherence, screen for mood changes or sexual side effects, and set realistic expectations ahead of the 12-month assessment.
If a dose is missed, patients should take it as soon as they remember on the same day. If a full day has passed, the missed dose should be skipped — doubling up is not recommended. Long-term adherence is essential, as discontinuation leads to reversal of any gains within approximately 9 to 12 months.
Combining finasteride with topical minoxidil is a recognised approach in UK clinical practice and may offer additive benefit. UK professional societies, including the Primary Care Dermatology Society (PCDS) and the British Association of Dermatologists (BAD), provide guidance on the management of androgenetic alopecia, including combination therapy options.
Potential Side Effects and MHRA Safety Guidance
Sexual side effects including reduced libido and erectile dysfunction affect approximately 1–4% of users and are generally reversible on stopping. The MHRA's 2024 update requires patients to stop finasteride immediately and seek urgent help if they experience depression or thoughts of self-harm.
Finasteride is generally well tolerated, but it carries a recognised profile of adverse effects that patients should be made aware of before starting treatment. The most commonly discussed side effects relate to sexual function and include:
-
Decreased libido
-
Erectile dysfunction
-
Reduced ejaculate volume
-
Ejaculatory disorder
These effects are reported in a small proportion of users — clinical trial data suggest an incidence of approximately 1–4% — and are generally reversible upon discontinuation in most cases.
MHRA safety update (2024): The MHRA has strengthened the warnings for finasteride 1 mg following a review of psychiatric and sexual side effects. A patient alert card is now provided with finasteride 1 mg, which patients should read carefully before starting treatment. Key updated advice includes:
-
If you experience depression or thoughts of self-harm or suicide, stop taking finasteride 1 mg immediately and contact a doctor or go to your nearest emergency department without delay.
-
Report any mood changes, low mood, anxiety, or depression to your GP promptly.
-
Discuss any sexual side effects with your prescriber before making any changes to your treatment.
Some men have reported persistent sexual and psychiatric symptoms — including low mood, anxiety, and sexual dysfunction — that have continued after stopping finasteride. The mechanism and causality of these persistent effects remain uncertain and are under ongoing regulatory review. Patients should be made aware of this possibility before starting treatment.
PSA and prostate cancer screening: Finasteride reduces PSA levels by approximately 50% after six or more months of use. When interpreting PSA results in men who have been taking finasteride for at least six months, clinicians should apply an adjustment factor of 2 to obtain a corrected estimate. Importantly, any rise in PSA from the established nadir — even if the absolute value remains within the normal range — warrants further clinical evaluation to exclude prostate cancer.
Male breast cancer: Although rare, cases of male breast cancer have been reported in men taking finasteride. Patients should be advised to seek prompt medical review if they notice any breast changes, including a lump, breast pain, or nipple discharge.
Breast tenderness or enlargement (gynaecomastia): This is an uncommon but recognised side effect. Any persistent breast changes should be assessed to exclude other pathology.
Effects on fertility and semen parameters: The SmPC notes that reduced semen quality, including reduced sperm count and motility, has been reported in some men taking finasteride. These effects have generally been reversible after stopping treatment. Men with concerns about fertility should discuss this with their prescriber before starting finasteride.
Hypersensitivity reactions: Allergic reactions, including rash, itching, urticaria, and swelling of the lips and face (angioedema), have been reported rarely. Patients experiencing these symptoms should stop the medication and seek urgent medical advice.
Suspected side effects should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Healthcare professionals and patients can both submit reports.
Accessing Finasteride Through the NHS or Private Prescription
Finasteride for hair loss is not routinely prescribed on the NHS and is usually obtained via private prescription from a GP, dermatologist, or CQC-registered online service. Patients should ensure their provider and pharmacy are registered with the GMC and GPhC respectively.
In the UK, finasteride for male pattern hair loss is not routinely available on the NHS. NHS England lists hair-loss treatments among the items that should not routinely be prescribed in primary care, as androgenetic alopecia is generally classified as a cosmetic rather than a clinical condition. As a result, most men will need to access finasteride through private routes.
Private prescriptions for finasteride can be obtained through:
-
Private GP consultations — either in-person or via regulated online platforms.
-
Dermatology clinics — particularly useful where the diagnosis is uncertain or hair loss is complex. Dermatology referral is the appropriate route for diagnostic uncertainty or cases that do not follow a typical pattern; it is worth noting that trichologists are not a statutorily regulated profession in the UK, so dermatology review is preferred in clinically uncertain cases.
-
Regulated online pharmacies and telehealth services — several services in the UK offer remote consultations and prescriptions. Patients should verify that the provider is registered with the Care Quality Commission (CQC), that the prescriber is registered with the General Medical Council (GMC) or appropriate regulatory body, and that the pharmacy is registered with the General Pharmaceutical Council (GPhC).
Generic finasteride 1 mg is considerably more affordable than branded Propecia, and private prescription costs have reduced significantly in recent years, making it accessible to a broader population. Patients should be cautious about purchasing finasteride from unregulated online sources without a valid prescription, as product quality and safety cannot be guaranteed.
In exceptional circumstances — for example, where hair loss is causing significant psychological distress — a GP may consider referral to an NHS dermatologist for holistic assessment. Patients experiencing severe anxiety or depression related to hair loss should discuss this with their GP, as mental health support may be available through NHS pathways regardless of whether the hair loss treatment itself is NHS-funded.
Frequently Asked Questions
How long does finasteride take to work for hair loss?
Most men notice a slowing of hair loss within 3 to 6 months of starting finasteride, with measurable regrowth typically becoming visible after 6 to 12 months. Maximum benefit is generally achieved after around 2 years of continuous daily use, though individual responses vary.
What happens if I stop taking finasteride?
If you stop taking finasteride, DHT levels return to baseline within weeks and any hair you have retained or regrown will typically be lost again within 9 to 12 months. Finasteride is a long-term management strategy rather than a cure, so ongoing daily use is needed to maintain its benefits.
Can women use finasteride for hair loss in the UK?
Finasteride is not licensed for hair loss in women in the UK, and the MHRA advises that it must not be used by women who are pregnant or may become pregnant due to the risk of foetal harm. Some specialist dermatologists may consider it off-label in post-menopausal women, but this requires careful clinical assessment.
What is the difference between finasteride and minoxidil for hair loss?
Finasteride is an oral tablet that works hormonally by reducing DHT, while minoxidil is a topical (or oral) treatment that works by improving blood flow to hair follicles through a different mechanism. The two treatments can be used together, and UK clinical guidance recognises combination therapy as a recognised approach that may offer additive benefit.
Is finasteride safe to take long term?
Finasteride is generally well tolerated with long-term use, but it carries recognised risks including sexual side effects and, as highlighted in the MHRA's 2024 safety update, psychiatric effects such as depression. Men taking finasteride long term should also be aware that it reduces PSA levels by around 50%, which must be factored in during prostate cancer screening.
How do I get a private prescription for finasteride in the UK?
You can obtain a private prescription for finasteride through a private GP, a dermatology clinic, or a CQC-registered online telehealth service. Always check that the prescriber is registered with the GMC and that the dispensing pharmacy is registered with the GPhC before purchasing.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
